Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
This is a phase 1b study, which means that the purpose of the study is to establish the maximum dose of a pill drug called BYL719, when given with a standard treatment for patients with head and neck squamous cell cancer.
Head and Neck Squamous Cell Cancer
DRUG: Cetuximab|DRUG: BYL719|RADIATION: IMRT (Intensity-Modulated Radiation Therapy)
determine the phase II-recommended dose of BYL719, Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable., 2 years
Adverse events, Adverse events (AEs) will be assessed according to NCI common toxicity criteria (CTC) version 4. DLT is defined as any toxicity requiring radiotherapy treatment delay of ≥ 7 calendar days, or any ≥ Grade 3 toxicity (other than those excluded from the DLT definition, below). Patients who require dose reduction in BYL719 due to toxicity will be deemed to have experienced DLT., 2 years
This is a phase 1b study, which means that the purpose of the study is to establish the maximum dose of a pill drug called BYL719, when given with a standard treatment for patients with head and neck squamous cell cancer.